Contract award notice
Results of the procurement procedure
Section I: Contracting
entity
I.1) Name and addresses
NHS Wales Shared Services Partnership
Procurement Services, Cardiff and Vale University Local Health Board, Woodlands House, Maes-Y-Coed Road
Cardiff
CF14 4HH
UK
Telephone: +44 02921836450
E-mail: emma.lane@wales.nhs.uk
NUTS: UK
Internet address(es)
Main address: http://www.procurement.wales.nhs.uk
Address of the buyer profile: http://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Purchase of Apheresis Spectra Optia machines with maintenance and consumables
Reference number: CAV-STA (22-23) 5
II.1.2) Main CPV code
33140000
II.1.3) Type of contract
Supplies
II.1.4) Short description
NHS Wales Shared Services Partnership who are hosted by Velindre NHS Trust acting on behalf of Cardiff and Vale University Local Health Board wish to inform the market that they intend to award a contract for the purchase of three Apheresis Spectra Optia machines with maintenance and consumables.
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.2) Additional CPV code(s)
33194210
II.2.3) Place of performance
NUTS code:
UKL22
II.2.4) Description of the procurement
The South Wales Blood and Marrow Transplant Programme (SWBMT) serves adults and children within the catchment area of mid, west and south Wales, comprising six of the seven Welsh Local Health Boards (LHBs), with a combined population of approximately 2.4 million and accounting for over three-quarters of the Welsh population.
The Children’s oncology unit at the Children’s Hospital for Wales (CHfW) is the only unit in Wales that provides treatment for children with complex haematological conditions (such as sickle cell anaemia or treatments requiring cell collection for re-infusion post chemotherapy). The unit works closely in partnership with the adult haematology department as the services are small and the processes required to manage the paediatric conditions are carried out rarely. Therefore education, training and maintaining competence are dependent on working in partnership with the adult service.
The three Spectra Optia machines required to carry out apheresis, cell collection or cell processing procedures in this speciality are now of an age where they require replacement. The machine carries out highly specialist processes so they have to be reliable and accurate.
This notice is for the purchase of three Spectra Optia machines including maintenance for up to five years (after the one year warranty) and consumables.
II.2.5) Award criteria
Quality criterion: as per procurement docs
/ Weighting: 100
Price
/ Weighting:
0
II.2.11) Information about options
Options:
Yes
Description of options:
Up to five years for maintenance (after the one year warranty) and consumables.
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Award of a contract without prior publication of a call for competition
Justification for selected award procedure:
The procurement falls outside the scope of application of the Directive
Explanation
The apheresis service at Cardiff and Vale UHB provides:
1. Donor apheresis (collection of haematopoietic progenitor cells [HPC, A] and peripheral blood mononuclear cells for immediate therapeutic use as well as a precursor for manufacture into chimaeric antigen receptor (CAR) T-cells) [MNC, A]
2. Therapeutic apheresis including plasma exchange and red blood cell exchange
NICE Medical Technologies Guidance [MTG28], published the 2nd March 2016 and updated August 2020, concluded, inter alia, that the Spectra Optia is effective for managing red blood cell exchange in managing sickle cell disease and further noted that use of the Spectra Optia is likely to result in significant cost savings in most patients with sickle cell disease. NICE further noted that adopting the Spectra Optia is estimated to result in cost savings per person per year. As a result of this Guidance, NHSE has adopted the Spectra Optia system for its apheresis services.
Given the need to perform both donor and therapeutic apheresis, It is imperative that the chosen platform is able to perform both functions effectively and efficiently. The Spectra Optia is the only system to have been reviewed and approved by NICE [MTG28] for therapeutic red cell exchange with resultant savings to the NHS. This is a service provided to the Health Board's patient population with sickle cell disease.
In addition, the Paediatrics department requires the same equipment throughout the Health Board to align with Adult services ensuring standardised patient treatment and care along with staff training. Any change in equipment would mean that staff would require retraining and through the initial transition there is a greater risk of use error due to unfamiliarity.
On the above basis, the Health Board is issuing this notice and applying a 10 day standstill period prior to award of the purchase of three machines and a contract for up to five years for maintenance (after the one year warranty) and consumables.
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.1) Previous publication concerning this procedure
Notice number in the OJ S:
2022/S 000-036674
Section V: Award of contract
Contract No: CAV-STA (22-23) 5
A contract/lot is awarded:
No
V.1 Information on non-award
The contract/lot is not awarded
Other reasons (discontinuation of procedure)
Section VI: Complementary information
VI.3) Additional information
The value stated in this notice is the higher ceiling contract figure and may not be fully utilised as this will be dependent upon the volume of consumables ordered and maintenance years taken up.
(WA Ref:128018)
VI.4) Procedures for review
VI.4.1) Review body
High Court
London
UK
Internet address(es)
URL: http://www.procurement.wales.nhs.uk
VI.4.3) Review procedure
Precise information on deadline(s) for review procedures:
NHS Wales Shared Services Partnership on behalf of Cardiff and Vale University Health Board will allow a minimum 10 calendar day standstill period between notifying the award decision and awarding the contract.
VI.5) Date of dispatch of this notice
11/01/2023